JP2006517232A5 - - Google Patents

Download PDF

Info

Publication number
JP2006517232A5
JP2006517232A5 JP2006503445A JP2006503445A JP2006517232A5 JP 2006517232 A5 JP2006517232 A5 JP 2006517232A5 JP 2006503445 A JP2006503445 A JP 2006503445A JP 2006503445 A JP2006503445 A JP 2006503445A JP 2006517232 A5 JP2006517232 A5 JP 2006517232A5
Authority
JP
Japan
Prior art keywords
amphetamine
pharmaceutical combination
isomer
released
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006503445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006517232A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/003821 external-priority patent/WO2004071501A1/en
Publication of JP2006517232A publication Critical patent/JP2006517232A/ja
Publication of JP2006517232A5 publication Critical patent/JP2006517232A5/ja
Pending legal-status Critical Current

Links

JP2006503445A 2003-02-10 2004-02-10 Adhdの処置のためのエナンチオマーアンフェタミン組成物 Pending JP2006517232A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44579303P 2003-02-10 2003-02-10
US47392503P 2003-05-29 2003-05-29
PCT/US2004/003821 WO2004071501A1 (en) 2003-02-10 2004-02-10 Enantiomeric amphetamine compositions for the treatment of adhd

Publications (2)

Publication Number Publication Date
JP2006517232A JP2006517232A (ja) 2006-07-20
JP2006517232A5 true JP2006517232A5 (cg-RX-API-DMAC7.html) 2007-04-12

Family

ID=32871959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006503445A Pending JP2006517232A (ja) 2003-02-10 2004-02-10 Adhdの処置のためのエナンチオマーアンフェタミン組成物

Country Status (10)

Country Link
US (1) US20040220277A1 (cg-RX-API-DMAC7.html)
EP (1) EP1626709B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006517232A (cg-RX-API-DMAC7.html)
KR (1) KR20050119106A (cg-RX-API-DMAC7.html)
AT (1) ATE372112T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004210671A1 (cg-RX-API-DMAC7.html)
CA (1) CA2515394A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004008771T2 (cg-RX-API-DMAC7.html)
ES (1) ES2293223T3 (cg-RX-API-DMAC7.html)
WO (1) WO2004071501A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
EP1874274A2 (en) * 2005-04-06 2008-01-09 Mallinckrodt Inc. Matrix-based pulse release pharmaceutical formulation
WO2007041571A1 (en) * 2005-10-03 2007-04-12 Cambrex Charles City, Inc. Improved method of making amphetamine free base
ATE536867T1 (de) 2006-03-16 2011-12-15 Tris Pharma Inc Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
GB201002612D0 (en) * 2010-02-16 2010-03-31 Jagotec Ag Improvements in or relating to organic compounds
US10463633B2 (en) * 2010-04-23 2019-11-05 Kempharm, Inc. Therapeutic formulation for reduced drug side effects
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
WO2013059676A1 (en) * 2011-10-21 2013-04-25 Subhash Desai Compositions for reduction of side effects
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
IL288554B2 (en) * 2016-02-24 2024-02-01 Chemapotheca LLC Controlled release of amphetamine, drug meters and dosage forms with abuse deterrence
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
CA3221280A1 (en) 2021-06-03 2022-12-08 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
CA3239514A1 (en) * 2021-12-09 2023-06-15 Matthew J. Baggott Specialized combinations for mental disorders or mental enhancement

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6056968A (en) * 1997-03-11 2000-05-02 Darwin Discovery Limited Pharmaceutical drug dosage forms providing different release rates
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
WO2000059481A1 (en) * 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
TWI291871B (en) * 2000-11-01 2008-01-01 Cognition Pharmaceuticals Llc Pharmaceutical compositions and use of amphetamine compounds for improving memory and learning
AU2003208170B2 (en) * 2002-02-28 2006-11-23 Birseck Pty Ltd Treatment of effect of chemicals with their ultradilute stereoisomers
AU2003231156A1 (en) * 2002-04-30 2003-11-17 Npd Llc Multi-phasic delivery via transmucosal absorption of appetite suppressants and craving reduction medicaments
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts

Similar Documents

Publication Publication Date Title
Chengappa et al. Inositol as an add‐on treatment for bipolar depression
Healy-Stoffel et al. N-3 (Omega-3) fatty acids: effects on brain dopamine systems and potential role in the etiology and treatment of neuropsychiatric disorders
Mathews et al. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date
AU2024203022A1 (en) LSD dose identification
EP1626709B1 (en) Enantiomeric amphetamine compositions for the treatment of adhd
WO2012129551A1 (en) Methods and compositions for treatment of attention deficit disorder
UA70315C2 (en) Pharmaceutical composition comprising metformin anpharmaceutical composition comprising metformin and fibrate useful for formulations intended for lowd fibrate useful for formulations intended for lowering hyperglycemia ering hyperglycemia
US20130190275A1 (en) Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders
WO2009128058A1 (en) Psycho-pharmaceuticals
JP2008519811A (ja) 下肢静止不能症候群の治療
WO2017153846A2 (en) A mazindol ir/sr multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (adhd)
US20210353559A1 (en) Composition and method for treating neurological disease
JP5478245B2 (ja) ナルトレキソンの徐放型配合物
US10500170B2 (en) Composition and method for treating neurological disease
CA3079509C (en) Synergic drug combination of the active enantiomer (s)-ketorolac and gabapentin for the treatment of neuropathic pain
Buccafusco et al. Potential cognitive actions of (n-propargly-(3r)-aminoindan-5-yl)-ethyl, methyl carbamate (tv3326), a novel neuroprotective agent, as assessed in old rhesus monkeys in their performance of versions of a delayed matching task
ES2426232T3 (es) Nueva composición para el tratamiento de trombocitemia esencial
CA3211578A1 (en) Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression
JP6992004B2 (ja) パーキンソン病患者において転倒を低減するためのアセチルコリンエステラーゼ阻害剤およびイダロピルジンの使用
EP2218462A1 (en) Pharmaceutical preparation for the treatment of depressive pathologies, comprising a protein with a high tryptophan/LNAAs (Large Neutral Amino Acids) ratio
Bentley et al. A one-year open-label study of the safety and efficacy of lamotrigine in the treatment of bipolar depression
RU2270010C2 (ru) Фармацевтическая композиция, обладающая снотворным действием
Duggal et al. Venlafaxine-induced orthostatic hypotension
Demartinis et al. Efficacy and tolerability of sertraline in treating anxious depression
HK1091117B (en) Enantiomeric amphetamine compositions for the treatment of adhd